Cargando…

Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?

Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation...

Descripción completa

Detalles Bibliográficos
Autores principales: Sousa, Lirlândia P., Pinho, Vanessa, Teixeira, Mauro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323156/
https://www.ncbi.nlm.nih.gov/pubmed/32557557
http://dx.doi.org/10.1111/bph.15164
_version_ 1783551751931035648
author Sousa, Lirlândia P.
Pinho, Vanessa
Teixeira, Mauro M.
author_facet Sousa, Lirlândia P.
Pinho, Vanessa
Teixeira, Mauro M.
author_sort Sousa, Lirlândia P.
collection PubMed
description Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation are now known. Overall, mediators of resolution tend to decrease inflammatory responses and provide normal or greater ability of the host to deal with infection. In the lung, it seems that pro‐resolution molecules, or strategies that promote their increase, tend to suppress inflammation and lung injury and facilitate control of bacterial or viral burden. Here, we argue that the demonstrated anti‐inflammatory, pro‐resolving, anti‐thrombogenic and anti‐microbial effects of such endogenous mediators of resolution may be useful in the treatment of the late stages of the disease in patients with COVID‐19.
format Online
Article
Text
id pubmed-7323156
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-73231562020-06-29 Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19? Sousa, Lirlândia P. Pinho, Vanessa Teixeira, Mauro M. Br J Pharmacol Mini‐reviews Inflammation is generally accepted as a component of the host defence system and a protective response in the context of infectious diseases. However, altered inflammatory responses can contribute to disease in infected individuals. Many endogenous mediators that drive the resolution of inflammation are now known. Overall, mediators of resolution tend to decrease inflammatory responses and provide normal or greater ability of the host to deal with infection. In the lung, it seems that pro‐resolution molecules, or strategies that promote their increase, tend to suppress inflammation and lung injury and facilitate control of bacterial or viral burden. Here, we argue that the demonstrated anti‐inflammatory, pro‐resolving, anti‐thrombogenic and anti‐microbial effects of such endogenous mediators of resolution may be useful in the treatment of the late stages of the disease in patients with COVID‐19. John Wiley and Sons Inc. 2020-07-08 2020-09 /pmc/articles/PMC7323156/ /pubmed/32557557 http://dx.doi.org/10.1111/bph.15164 Text en © 2020 The British Pharmacological Society
spellingShingle Mini‐reviews
Sousa, Lirlândia P.
Pinho, Vanessa
Teixeira, Mauro M.
Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?
title Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?
title_full Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?
title_fullStr Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?
title_full_unstemmed Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?
title_short Harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID‐19?
title_sort harnessing inflammation resolving‐based therapeutic agents to treat pulmonary viral infections: what can the future offer to covid‐19?
topic Mini‐reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323156/
https://www.ncbi.nlm.nih.gov/pubmed/32557557
http://dx.doi.org/10.1111/bph.15164
work_keys_str_mv AT sousalirlandiap harnessinginflammationresolvingbasedtherapeuticagentstotreatpulmonaryviralinfectionswhatcanthefutureoffertocovid19
AT pinhovanessa harnessinginflammationresolvingbasedtherapeuticagentstotreatpulmonaryviralinfectionswhatcanthefutureoffertocovid19
AT teixeiramaurom harnessinginflammationresolvingbasedtherapeuticagentstotreatpulmonaryviralinfectionswhatcanthefutureoffertocovid19